It has been shown that the hypothalamic-pituitary-adrenal (HPA) axis responses to immune-derived stimuli in particular can be modulated by nitric oxide (NO). In the present study we examined the effect of endogenous and exogenous NO on the HPA axis responses to neural stimuli which are not related to immune functions. Intracerebroventricular injection of NOR-3, a donor of NO, had no effect on basal HPA axis activity but significantly attenuated the secretion of median eminence (ME) CRH-41 as well as the serum ACTH and corticosterone (CS) in response to acute photic stimulation in a dose-dependent manner. Intracerebroventricular administration of N-ω-nitro-L-arginine methyl ester (L-NAME), a general NOS inhibitor, significantly enhanced ACTH and CS responses to this stress but did not change the basal levels of these hormones. On the other hand, i.c.v. injection of aminoguanidine, an inhibitor of inducible NO synthase (NOS) but not of neuronal NOS, did not affect the HPA axis responses to photic stimulation. These results suggest that: (1) NO is involved in modulation of the HPA axis responses to neural stimuli which are not dependent on immune factors, (2) the effect of NO is mediated by inhibition of hypothalamic ME CRH-41 secretion, and (3) this effect is probably mediated by neuronal NOS and not by inducible NOS.

Keywords:
Nitric oxide, Nitric oxide synthase, Stress, Corticotropin, Corticotropin-releasing hormone, Adrenal steroids
1.
Whitnall MH: Regulation of the hypothalamic corticotropin releasing hormone neurosecretory system. Prog Neurobiol 1993;40:573–629.
2.
Feldman S, Conforti N, Weidenfeld J: Limbic pathways and hypothalamic neurotransmitters mediating adrenocortical response to neural stimuli. Neurosci Biobehav Rev 1995;19:235–240.
3.
Nelson RJ, Kriegsfeld LJ, Dawson VL, Dawson TM: Effects of nitric oxide on neuroendocrine function and behavior. Front Neuroendocrinol 1997;18:463–491.
4.
Brann DW, Bhat GK, Lamar CA, Mahesh VB: Gaseous transmitters and neuroendocrine regulation. Neuroendocrinology 1997;65:385–395.
5.
Arevalo R, Sanchez F, Alonso JR, Carretero J, Vazquez R, Aijon J: NADPH-diaphorase activity in the hypothalamic magnocellular neurosecretory nuclei of the rat. Brain Res Bull 1992;28:599–603.
6.
Grossman A, Costa A, Forsling ML, Jacobs R, Kostoglou Athanassiou I, Nappi G, Navarra P, Satta MA: Gasesous neurotransmitters in the hypothalamus. The roles of nitric oxide and carbon monoxide in neuroendocrinology. Horm Metab Res 1997;29:477–482.
7.
Bhat GK, Mahesh VB, Lamar CA, Ping L, Aguan K, Brann DW: Histochemical localization of nitric oxide neurons in the hypothalamus: Association with gonadotropin-releasing hormone neurons and co-localization with N-methyl-D-aspartate receptors. Neuroendocrinology 1995;62:187–197.
8.
Gustafsson BI, Oland LD, Davison JS: Nitric oxide synthase, oxytocin and vasopressin immunoreactivities in the paraventricular, supraoptic and vagal nuclei of the ferret. J Physiol Paris 1997;91:215–216.
9.
Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H: Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121–1131.
10.
Yun HY, Dawson VL, Dawson TM: Nitric oxide in health and disease of the nervous system. Mol Psychiatry 1997;2:300–310.
11.
Lee SC, Dickson DW, Liu W, Brosnan CF: Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol 1993;46:19–24.
12.
Moncada S, Higgs A: The L-arginine nitric oxide pathway. N Engl J Med 1993;329:2002–2012.
13.
Schuman EM, Madison DV: Nitric oxide and synaptic function. Annu Rev Neurosci 1994;17:153–183.
14.
Rivier C: Blockade of nitric oxide formation augments adrenocorticotropin released by blood-borne interleukin-1 beta: Role of vasopressin, prostaglandins, and alpha 1-adrenergic receptors. Endocrinology 1995;136:3597–3603.
15.
Kim CK, Rivier C: Influence of nitric oxide synthase inhibitors on the ACTH and cytokine responses to peripheral immune signals. J Neuroendocrinol 1998;10:353–362.
16.
Satta MA, Jacobs RA, Kaltsas GA, Grossman AB: Endotoxin induces interleukin 1β and nitric oxide synthase mRNA in rat hypothalamus and pitutiary. Neuroendocrinology 1998;67:109–116.
17.
Hashimoto K, Nishioka T, Tojo C, Takao T: Nitric oxide plays no role in ACTH release induced by interleukin-1 beta, corticotropin-releasing hormone, arginine vasopressin and phorbol myristate acetate in rat pituitary cell cultures. Endocr J 1995;42:435–439.
18.
Weidenfeld J, Feldman S: Glucocorticoid feedback regulation of adrenocortical responses to neural stimuli: Role of CRF-41 and corticosteroid type I and type II receptors. Neuroendocrinology 1993;58:49–56.
19.
Kita Y, Hirasawa Y, Maeda K, Nishio M, Yoshida K: Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. Eur J Pharmacol 1994;257:123–130.
20.
Ayers NA, Kapas L, Krueger JM: The inhibitory effects of L-NAME on nitric oxide synthase activity vary among brain regions in vivo but not in vitro. Neurochem Res 1997;22:81–86.
21.
Weidenfeld J, Crumeyrolle-Arias M, Haour F: Effect of bacterial endotoxin and interleukin 1 on prostaglandin biosynthesis by the hippocampus of mouse brain: Role of interleukin 1 receptors and glucocorticoids. Neuroendocrinology 1995;62:39–46.
22.
Weidenfeld J, Itzik A, Feldman S: Effect of glucocorticoids on the adrenocortical axis responses to electrical stimulation of the amygdala and the ventral noradrenergic bundle. Brain Res 1997;754:187–194.
23.
Burnett AL, Lowenstein CJ, Bredt DS, Chang TSK, Snyder SH: Nitric oxide: A physiologic mediator of penile erection. Science 1992;257:401–403.
24.
Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M, Aiso S, Kato R, Asai M: Involvement of interleukin 1 in immobilization stress induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995;15:1961–1970.
25.
Costa A, Trainer P, Besser M, Grossman A: Nitric oxide modulates the release of corticotropin releasing hormone from the rat hypothalamus in vitro. Brain Res 1993;605:187–192.
26.
Karanth S, Lyson K, McCann SM: Role of nitric oxide in interleukin 2 induced corticotropin releasing factor release from incubated hypothalami. Proc Natl Acad Sci USA 1993;90:3383–3387.
27.
Brenner T, Brocke S, Szafer F, Sobel RA, Parkinson JF, Perez DH, Steinman L: Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol 1997;158:2940–2946.
28.
Bains JS, Ferguson AV: Nitric oxide depolarizes type II paraventricular nucleus neurons in vitro. Neuroscience 1997;79:149–159.
29.
McCann SM, Kimura M, Karanth S, Yu WH, Rettori V: Nitric oxide controls the hypothalamic pituitary response to cytokines. Neuroimmunomodulation 1997;4:98–106.
30.
Kishimoto J, Tsuchiya T, Emson PC, Nakayama Y: Immobilization induced stress activates neuronal nitric oxide synthase (nNOS) mRNA and protein in hypothalamic pituitary adrenal axis in rats. Brain Res 1996;720:159–171.
31.
Plotsky PM, Cunningham ET, Widmaier EP: Catecholaminergic modulation of corticotropin releasing factor and adrenocorticotropin secretion. Endocr Rev 1989;10:437–458.
32.
Weidenfeld J, Abramsky O, Ovadia H: Evidence for the involvement of the central adrenergic system in interleukin 1 induced adrenocortical response. Neuropharmacology 1989;28:1411–1414.
33.
Chu HP, Etgen AM: Effects of nitric oxide on stimulated release of norepinephrine from female rat hypothalamic slices. Brain Res 1996;74:60–67.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.